Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This team has identified a subset of childhood Acute Lymphoblastic Leukemia (ALL) with specific genetic abnormalities in the leukemia cells (Ph-like ALL) that has poor survival. Some Ph-like ALL patients have genetic abnormalities that make their leukemia cells sensitive to a targeted therapy (dasatinib), which has many fewer side effects than chemotherapy. This consortium is using a COG clinical trial to help identify which children should respond to dasatinib, and then will add this targeted therapy to their chemotherapy to try to improve survival. Awarded at the University of Colorado and transferred to the Children's Hospital of Philadelphia. Funds administered by the Children's Hospital of Philadelphia.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's:COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

Neuroblastoma is one of the most common solid tumors of childhood, and patients have very low survival if it recurs after initial treatment. Natural killer (NK) cells are white blood cells that are part of your body's natural defense against cancer, and these cells are particularly good at killing neuroblastoma when they work together with immune stimulators and anti-cancer antibodies. This team has developed a new way to grow large numbers of very active NK cells. The project is testing whether NK cells in combination with the anti-neuroblastoma antibody, ch14.18, and the immune activator, lenalidomide, will improve survival for children with neuroblastoma. Awarded at University of Texas M.D. Anderson Cancer Center and transferred to The Research Institute at Nationwide Children's. Funds administered by The Research Institute at Nationwide Children's Hospital.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Multimodal immunotherapy for neuroblastoma Consortium. For a description of this project, see the consortium grant made to the lead institution: The Research Institute at Nationwide Children's Hospital, Columbus, OH.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.